Hubei July basic drug purchase: still prefer antibiotics and traditional Chinese medicine injection

On August 7, Hubei provincial centralized purchasing center of basic drugs released the purchasing situation of basic drugs in July According to the comprehensive statistics of the top 20 drugs purchased, the market of basic drugs in Hubei still preferred antibiotics and traditional Chinese medicine injections Since June, the proportion of antibiotic purchase amount has declined, which has been maintained at about 40% for two consecutive months, while the proportion of traditional Chinese medicine injection in the first half of the year has been maintained at 30% According to the data of July, in addition to the traditional procurement categories such as glucose injection and sodium chloride injection, the procurement amount of Xueshuantong and Xuesaitong, the big varieties of cardiovascular and cerebrovascular drugs, ranks first Among them, Zhongheng group's three major products of Xueshuantong for injection have a total purchase amount of 4.4 million yuan, leading the purchase of traditional Chinese medicine injection in the province; the contribution of Xuesaitong for injection (freeze-dried), the exclusive product of Heilongjiang Zhenbaodao and Kunming Pharmaceutical, to the basic drug market in the province, can not be underestimated, with 3.9 million yuan and 2.62 million yuan respectively In the first half of this year, reviewing the competition in Hubei basic drug market, Zhongheng group is slightly better than the latter two pharmaceutical companies In addition, antibiotic series has always been the favorite in Hubei basic drug market In the first five months of this year, the proportion of antibiotic drug purchase has been maintained at about 60% After the province changed the anti drug restriction from special treatment to normal management at the end of May, the proportion of antibiotics began to decline rapidly, and now it is maintained at 40% for two consecutive months Among them, the antibiotic with the largest purchase amount is still clindamycin hydrochloride injection produced by Yichang humanwell, a subsidiary of humanwell pharmaceutical Holding Co., Ltd., but the proportion is only 6%.